Quick Answer
Vivos Therapeutics, Inc. reported Net Income Loss of -$11.14 million for the year ending 2024.
- Vivos Therapeutics, Inc. showed an increase of +18.0% in Net Income Loss from 2023 to 2024.
- This data is from Vivos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$2.58 million | Q2 2020: -$1.41 million | Q3 2020: -$1.81 million | Q1 2021: -$3.40 million | Q2 2021: -$4.04 million | Q3 2021: -$5.45 million | Q1 2022: -$5.33 million | Q2 2022: -$6.99 million | Q3 2022: -$5.43 million | Q1 2023: -$1.70 million | Q2 2023: -$5.53 million | Q3 2023: -$2.09 million | Q1 2024: -$3.76 million | Q2 2024: -$1.93 million | Q3 2024: -$2.62 million | Q1 2025: -$3.86 million | Q2 2025: -$5.01 million | Q3 2025: -$5.40 million.
- Over the full 6 years of available data (2019 to 2024), Vivos Therapeutics, Inc.'s Net Income Loss has declined by 3.5%.
- Historical annual values: Fiscal year 2024: -$11.14 million | Fiscal year 2023: -$13.58 million | Fiscal year 2022: -$23.85 million | Fiscal year 2021: -$20.29 million | Fiscal year 2020: -$12.06 million | Fiscal year 2019: -$10.75 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: